// App-Quantinova.ai

: Prospective clinical study of a prostate cancer (PCa) rule-out blood test for PSA gray zone patients using a sensitive circulating tumor cell assay.

Researchers

Presenter

  • SEE-TONG Pang

Principal Investigators

  • Ying-Hsu Chang

  • Po-Hung Lin

  • Ying Chang

  • Drew Watson

  • Oscar Segurado

  • Si-Hong Lu

  • Jen-chia Wu

  • Jr-Ming Lai

  • Hung-Jen Shao

  • Shih-En Chang

  • Ben Hsieh

  • Mana Javey

  • Rui Mei

Medical Centers

  • Chang Gung University and Hospital at LinKou, Taoyuan, Taiwan

  • Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

  • Academia Sinica Taipei, Taipei, Taiwan

  • Kit Bio Inc, LOS Altos, CA

  • Medic Affairs Consulting LLC, San Jose, CA

  • CellMax Life, Sunnyvale, CA

Locations

  • Taiwan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Cytokeratin 18

  • Epithelial Cell Adhesion Molecule

  • Folate Hydrolase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Prospective

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved